PT-141

PT-141 (bremelanotide) is a melanocortin receptor agonist that acts in the brain to influence sexual desire. Unusually for the peptides covered here, the molecule is FDA-approved — it is the active ingredient in the prescription drug Vyleesi, cleared in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. However, "research use only" PT-141 sold online is not that approved product. This page is purely educational and is not medical advice; any decision about PT-141 belongs with a licensed clinician.

Important: There is a real, FDA-approved version of this molecule (Vyleesi) with specific labeling, warnings, and usage limits. Unregulated "research" vials are not the same thing and have not been evaluated by the FDA for safety, identity, purity, or potency.

What is PT-141?#

PT-141 is the common name for bremelanotide, a synthetic cyclic peptide. It is a metabolite and analog of an earlier compound (melanotan II) and was developed specifically for its central effects on sexual desire rather than for tanning, muscle, or recovery.

The molecule works as a melanocortin receptor agonist. It non-selectively activates several melanocortin receptor subtypes, with activity at MC1R and MC4R being the most relevant at therapeutic levels. MC4R, in particular, is tied to brain pathways involved in sexual motivation.

In its approved form, bremelanotide is marketed as Vyleesi, supplied as a prefilled subcutaneous autoinjector. The "PT-141" name is most often used for non-approved, "research" material sold as a lyophilized powder.

How does PT-141 work?#

PT-141 is notable because it acts centrally, in the brain, rather than on blood vessels. This is different from common erectile-dysfunction drugs (such as PDE5 inhibitors), which act on the vascular system to affect blood flow.

• PT-141 activates melanocortin receptors in the central nervous system, primarily MC4R.
• This activity is thought to engage brain regions and signaling associated with sexual motivation and arousal.
• Because the effect originates in the brain rather than the bloodstream, its mechanism is described as neurological/central.

The exact downstream chain of events is still being characterized. Even in the FDA labeling, the precise mechanism by which melanocortin signaling improves sexual desire and related distress is described as not known.

What is PT-141 studied for?#

The approved use is narrow and specific; other uses are investigational. PT-141 is not an approved treatment for anything outside the labeled HSDD indication.

In the pivotal trials, more women using bremelanotide met responder criteria for improved sexual desire and reduced distress than those on placebo, though the absolute difference was modest. The approval reflects a benefit in a specific, distress-causing condition — not a general "libido booster" for the broad population.

Is PT-141 legal and FDA-approved?#

The molecule is FDA-approved. Bremelanotide was approved by the FDA in 2019 as Vyleesi (bremelanotide injection) for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Here, "acquired" means the low desire developed after a period of normal desire, and "generalized" means it occurs regardless of partner, situation, or type of stimulation.

The crucial distinction: that approval applies to the specific Vyleesi product, dispensed by prescription with FDA-reviewed labeling and warnings. Vials of "PT-141" sold "for research use only" are not the approved medicine. They have not been evaluated by the FDA for safety, identity, purity, sterility, or potency, and using them is not equivalent to taking the approved drug.

Nothing here is legal advice; regulations vary by country and change over time. Check the rules in your jurisdiction.

How is PT-141 dosed in research?#

There is an FDA-approved product with specific labeled instructions, a defined route, and an explicit limit on how often it may be used — but WikiPeps does not publish dosing protocols or amounts for any peptide, including this one. Copying a number from a website while using unregulated "research" material is not the same as taking a labeled, prescribed medicine under supervision.

Dosing, eligibility, the maximum dosing frequency, and the contraindications and warnings on the approved label are all medical decisions. If you are considering bremelanotide, that conversation belongs with a licensed clinician who can confirm it is appropriate for you, prescribe the approved product, and monitor you.

How is PT-141 reconstituted?#

The approved product (Vyleesi) comes as a prefilled autoinjector and does not require mixing. The "research" form of PT-141 is typically supplied as a lyophilized (freeze-dried) powder that would have to be reconstituted with a sterile diluent. The general handling steps are outlined in the educational overview in this page's "how-to" data, but that overview covers sterile technique and storage only — it does not provide amounts.

That overview is educational only and does not tell anyone how much to use or instruct self-administration.

What are the safety considerations?#

Because an approved product exists, the safety profile of bremelanotide is better characterized than that of many research-only peptides — and that profile includes real, common side effects.

Key cautions from the approved labeling and published reviews:

• Nausea is very common — reported by roughly 40% of users, often most pronounced with the first dose, and sometimes severe enough to require treatment or to cause people to stop.
• Flushing, headache, vomiting, and injection-site reactions are also common.
• Transient cardiovascular effects. Bremelanotide can cause a temporary increase in blood pressure and a decrease in heart rate after each dose. For this reason the approved label advises against use in people with uncontrolled high blood pressure or known cardiovascular disease.
• Skin darkening (hyperpigmentation). A small percentage of users in trials developed focal hyperpigmentation (including the face, gums, and breasts); the risk appeared higher with more frequent dosing and in people with darker skin, and it did not always resolve.
• Rare liver injury (limited data). NIH's LiverTox rates bremelanotide as a possible rare cause of clinically apparent liver injury (likelihood score "D"), based on a single reported case; in the pre-approval trials, serum enzyme elevations occurred in similar proportions of treated and placebo participants, and overall clinical experience remains limited.
• Unregulated "research" material is an added, separate risk. Beyond the drug's own effects, "research-only" PT-141 has unknown purity, identity, dose accuracy, and sterility, which introduces hazards the approved product is designed to avoid.

Tell a clinician about any peptide you are considering, do not assume "research" material behaves like the approved drug, and seek prompt medical care for unexpected symptoms (for example, chest pain, severe headache, or a marked change in blood pressure).

The bottom line#

PT-141 (bremelanotide) is a centrally acting melanocortin receptor agonist that influences sexual desire from the brain rather than the bloodstream. It is genuinely FDA-approved as Vyleesi for HSDD in premenopausal women — a real medicine with a defined benefit, a defined indication, and well-documented side effects such as nausea, flushing, transient blood-pressure changes, and occasional skin darkening. But the approval applies to that specific product, not to "research-only" PT-141 sold online, which is unregulated and unverified. There is an approved label, but WikiPeps does not publish doses. Treat anything you read here as background for an informed conversation with a licensed clinician, not as medical advice. </content> </invoke>